Value of the lung immune prognostic index in patients with non‐small cell lung cancer initiating first‐line atezolizumab combination therapy: Subgroup analysis of the impower150 trial

Research output: Contribution to journalArticlepeer-review

7 Citations (Scopus)
5 Downloads (Pure)

Fingerprint

Dive into the research topics of 'Value of the lung immune prognostic index in patients with non‐small cell lung cancer initiating first‐line atezolizumab combination therapy: Subgroup analysis of the impower150 trial'. Together they form a unique fingerprint.

Medicine & Life Sciences